轻型缺血性脑卒中发病4.5h内患者重组组织型纤溶酶原激活剂静脉溶栓治疗的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of intravenous thrombolytic therapy with recombinant tissuetype plasminogen activator (Alteplase) on patients within 4.5 hours of the onset of mild ischemic stroke. Methods The clinical data of 60 patients with mild ischemic stroke admitted to our hospital from January 2018 to January 2019 were retrospectively analyzed, and were divided into the control group (n=30) and the Alteplase group (n=30) according to different treatment schemes. The control group was treated with conventional drugs, and the Alteplase group was intervened with Alteplase intravenous thrombolysis. The total effective rate, the national institutes of health stroke scale(NIHSS) score before and after treatment, the Barthel index (BI) score, and the intracranial hemorrhage rate and the incidence of vascular reocclusion after one-week treatment were compared between the two groups. Results The total effective rate of the Alteplase group was higher than that of the control group, the difference was statistically significant(P＜0.05). The NIHSS score of the Alteplase group was lower than that of the control group, and the BI score was higher than that of the control group, the incidence of reocclusion was lower than that of the control group, the differences were statistically significant (P＜0.05). There was no significant difference in the intracranial bleeding rate between the two groups(P＞0.05).Conclusion The application of Alteplase to treat patients with mild ischemic stroke within 4.5 hours of onset can improve neurological deficits, improve daily living ability, and is highly safe.

Key words： Ischemic stroke Recombinant tissue-type plasminogen activator Intravenous thrombolysis Neurological function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHONG Rui

Cite this article:

ZHONG Rui. Clinical effect of intravenous thrombolytic therapy with recombinant tissue-type plasminogen activator on patients within 4.5 hours of the onset of mild ischemic stroke[J]. 中国当代医药, 2020, 27(7): 55-57.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I7/55

[1]	曹朝阳，李明，朱新建，等.重组组织型纤溶酶原激活药静脉溶栓治疗发病4.5 h 内急性脑梗死的疗效和安全性[J].武警医学，2017，28（7）：653-655.
[2]	中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志，2018，51（9）：666-682.
[3]	于若梅，曹谡涵，毛保义，等.重组组织型纤溶酶原激活剂静脉治疗轻型缺血性卒中患者的疗效分析[J].中国卒中杂志，2018，13（9）：16-20.
[4]	姜一，沈红健，陈蕾，等.静脉溶栓或桥接治疗对大动脉闭塞急性轻型缺血性脑卒中患者的疗效和安全性[J].第二军医大学学报，2018，39（11）：1214-1218.
[5]	刘勇，杨杰，陈洪，等.小剂量阿替普酶治疗高龄急性缺血性卒中患者的有效性和安全性[J].国际脑血管病杂志，2017，25（25）：812-813.
[6]	徐波，吴明瑞，汪娟.急性缺血性脑卒中患者静脉溶栓治疗对神经功能和凝血功能的影响[J].心脑血管病防治，2019，19（1）：78-80.
[7]	洪小琴，姜慧华.轻型缺血性卒中rt-PA 溶栓后24 h 内抗血小板治疗的疗效观察[J].中国地方病防治杂志，2017，31（9）：1047-1047.
[8]	石少亭，王林，柏玉兰，等.轻型卒中患者行重组组织型纤溶酶原激活剂静脉溶栓治疗的疗效观察[J].解放军医学院学报，2018，39（3）：196-199.
[9]	戴美芬，包黎刚，徐冬娟，等.轻型急性缺血性脑卒中患者静脉溶栓治疗的有效性和安全性分析[J].中华老年心脑血管病杂志，2016，18（10）：1070-1072.
[10]	林友榆，胡治平，黄银辉，等.血尿酸水平与重组组织型纤溶酶原激活剂静脉溶栓治疗急性缺血性脑卒中患者预后的关系[J].中华全科医师杂志，2016，15（3）：198-201.
[11]	苏航，康晓刚，何剑波.不同剂量阿替普酶联合瑞舒伐他汀治疗急性缺血性脑卒中疗效及安全性比较[J].药物评价研究，2016，39（5）：817-820.
[12]	赖娅莉.小剂量重组组织型纤溶酶原激活剂联合尿激酶静脉溶栓治疗急性脑梗死患者的临床疗效[J].实用心脑肺血管病杂志，2017，25（12）：92-93.
[13]	曹甜甜，徐海丽，贺延，等.重组组织型纤溶酶原激活剂静脉溶栓在急性缺血性脑卒中伴心房颤动患者不同治疗时间窗的疗效观察[J].山西医药杂志，2017，46（22）：103-105.
[14]	姜一，沈红健，陈蕾，等.静脉溶栓或桥接治疗对大动脉闭塞急性轻型缺血性脑卒中患者的疗效和安全性[J].第二军医大学学报，2018，39（11）：40-44.
[15]	徐娟，李志宁，刘腾飞，等.不同剂量重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死临床疗效及安全性的对比研究[J].实用心脑肺血管病杂志，2017，25（3）：62-65.